|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Cephalon
|
|
gptkbp:activities
|
integrase inhibitor
|
|
gptkbp:approves
|
gptkb:2007
gptkb:FDA
|
|
gptkbp:availability
|
gptkb:battle
|
|
gptkbp:brand
|
gptkb:Isentress
|
|
gptkbp:can_be_used_with
|
other antiretroviral drugs
|
|
gptkbp:clinical_trial
|
Phase III
treatment-naive patients
treatment-experienced patients
|
|
gptkbp:contraindication
|
hypersensitivity to raltegravir
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:has_ability
|
400 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Isentress
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:ingredients
|
C20 H19 F2 N3 O5 S
raltegravir
|
|
gptkbp:interacts_with
|
gptkb:rifampin
antacids
certain anticonvulsants
|
|
gptkbp:invention
|
gptkb:2022
|
|
gptkbp:is_atype_of
|
J05 A X08
|
|
gptkbp:is_used_for
|
HIV treatment
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
Isentress HD
|
|
gptkbp:pharmacokinetics
|
bioavailability 73%
half-life 9 hours
metabolized by UG T1 A1
|
|
gptkbp:provides_information_on
|
part of combination therapy
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:research_focus
|
treatment adherence
long-acting formulations
HIV resistance
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:scholarships
|
take with or without food
|
|
gptkbp:side_effect
|
gptkb:Insurance_Company
fatigue
headache
nausea
diarrhea
rash
insomnia
neuropathy
elevated liver enzymes
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
387315-06-0
|